Drug Profile
Research programme: HCV and HIV polymerase inhibitors - Roche
Alternative Names: RO-0622; RO-9187Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Roche
- Class Deoxyribonucleosides
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Nucleoside reverse transcriptase inhibitors; RNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hepatitis C; HIV-1 infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-C in Europe
- 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-1-infections in Europe
- 26 Apr 2009 Preclinical trials in HIV-1 infections in Europe (unspecified route)